Bridger Management Continues to Hold Stake in Heron Therapeutics (HRTX); Regeneron Pharmaceuticals (Put) (REGN) Holding Maintained by Capstone Investment Advisors Llc

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Capstone Investment Advisors Llc increased its stake in Regeneron Pharmaceuticals (Put) (REGN) by 3633.33% based on its latest 2018Q4 regulatory filing with the SEC. Capstone Investment Advisors Llc bought 10,900 shares as the company’s stock rose 19.30% with the market. The hedge fund held 11,200 shares of the health care company at the end of 2018Q4, valued at $4.18M, up from 300 at the end of the previous reported quarter. Capstone Investment Advisors Llc who had been investing in Regeneron Pharmaceuticals (Put) for a number of months, seems to be bullish on the $41.67 billion market cap company. The stock decreased 2.68% or $10.54 during the last trading session, reaching $382.94. About 1.25M shares traded or 82.54% up from the average. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 34.82% since April 15, 2018 and is uptrending. It has outperformed by 30.45% the S&P500. Some Historical REGN News: 03/04/2018 – REG-Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma; 10/03/2018 – NO PRALUENT SAFETY ISSUES ARISE IN MULTI-YEAR TRIAL – RESEARCHERS; 21/05/2018 – New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing Dupixent(R) (dupilumab) Improved Moderate-To-Severe Asthma; 11/05/2018 – Bayer: Eylea Treats Visual Impairment From Macular Degeneration; 22/04/2018 – DJ Regeneron Pharmaceuticals Inc, Inst Holders, 1Q 2018 (REGN); 03/04/2018 – EMA TO REVIEW DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR INADEQUATELY CONTROLLED MODERATE-TO-SEVERE ASTHMA; 01/05/2018 – REGENERON: EXPRESS SCRIPTS SELECTS PRALUENT EXCLUSIVE THERAPY; 19/03/2018 – #3 With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell $NVS $RHHBY $REGN; 21/05/2018 – Regeneron Pharma: Two Positive Phase 3 Trials Show DUPIXENT Improved Moderate-to-Severe Asthma; 01/05/2018 – Regeneron Pharma: Express Scripts to Pass on Savings to Eligible Patients From Participating Comml Health Plans

Bridger Management Llc increased its stake in Heron Therapeutics Inc (HRTX) by 8.39% based on its latest 2018Q4 regulatory filing with the SEC. Bridger Management Llc bought 192,245 shares as the company’s stock declined 0.99% while stock markets rallied. The hedge fund held 2.48 million shares of the health care company at the end of 2018Q4, valued at $64.39M, up from 2.29M at the end of the previous reported quarter. Bridger Management Llc who had been investing in Heron Therapeutics Inc for a number of months, seems to be bullish on the $1.95 billion market cap company. The stock increased 1.05% or $0.26 during the last trading session, reaching $24.92. About 801,893 shares traded. Heron Therapeutics, Inc. (NASDAQ:HRTX) has risen 35.57% since April 15, 2018 and is uptrending. It has outperformed by 31.20% the S&P500. Some Historical HRTX News: 10/05/2018 – HERON THERAPEUTICS INC – REAFFIRMS FULL-YEAR 2018 CINV FRANCHISE NET PRODUCT SALES GUIDANCE OF $60 MLN TO $70 MLN; 14/05/2018 – Carillon Tower Advisers Buys 1.8% of Heron Therapeutics; 11/04/2018 – Mylan: Acquired Global Marketing Rights for a Fast-Acting Meloxicam as Non-Narcotic Analgesic; 07/05/2018 – Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam; 15/05/2018 – Wellington Management Group Buys 3% of Heron Therapeutics; 21/03/2018 – INFORM P LYKOS SA LYKr.AT SAYS WINS MANAGEMENT OF HERON’S CUSTOMERS’ BILLS SINCE MARCH 1ST; 30/05/2018 – SEDOR PHARMACEUTICALS SAYS CO HAS GRANTED LOS ALTOS AN EXCLUSIVE LICENSE FOR CAPTISOL-ENABLED MELOXICAM FOR THE PEOPLE’S REPUBLIC OF CHINA; 10/04/2018 – FDA: Warning Letter – Blue Heron Bakery; 28/03/2018 – Heron’s Woodlawn Project on Track for Year-end Commissioning; 27/03/2018 – Recro Pharma: Data Shows IV Meloxicam Provides Rapid and Sustained Pain Relief Following Bunionectomy Surgery

Capstone Investment Advisors Llc, which manages about $16.83 billion and $8.10B US Long portfolio, decreased its stake in Union Pac Corp (NYSE:UNP) by 16,991 shares to 6,009 shares, valued at $831,000 in 2018Q4, according to the filing. It also reduced its holding in Cleveland Cliffs Inc by 3.00M shares in the quarter, leaving it with 12.00M shares, and cut its stake in Duke Energy Corp New (NYSE:DUK).

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Nasdaq.com which released: “5 Promising Biotech Stocks That Could Be Takeover Targets – Nasdaq” on March 29, 2019, also Bizjournals.com with their article: “Peninsula biotech lines up chance to crack the peanut allergy nut – San Francisco Business Times” published on March 25, 2019, Nasdaq.com published: “Inovio Closes Enrollment in Brain Cancer Study Before Time – Nasdaq” on April 02, 2019. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Nasdaq.com and their article: “REGN Makes Notable Cross Below Critical Moving Average – Nasdaq” published on April 12, 2019 as well as Globenewswire.com‘s news article titled: “Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth – GlobeNewswire” with publication date: March 25, 2019.

Since December 12, 2018, it had 0 insider purchases, and 4 insider sales for $55.44 million activity. 131,115 shares valued at $54.04 million were sold by Sanofi on Friday, March 8. $734,310 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by GOLDSTEIN JOSEPH L. VAGELOS P ROY sold $2,294 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Wednesday, December 12.

Investors sentiment decreased to 1.13 in Q4 2018. Its down 0.01, from 1.14 in 2018Q3. It fall, as 52 investors sold REGN shares while 165 reduced holdings. 72 funds opened positions while 174 raised stakes. 77.33 million shares or 9.82% more from 70.41 million shares in 2018Q3 were reported. 200 are held by Paradigm Asset Mngmt Company Ltd Company. Product Partners Ltd has invested 0.58% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Hartford Investment Mgmt Co invested in 8,529 shares or 0.1% of the stock. Advisory Ntwk Ltd Liability holds 894 shares or 0.03% of its portfolio. Cibc Ww reported 25,942 shares. Veritable Lp owns 2,269 shares or 0.02% of their US portfolio. Westpac Bk Corporation has invested 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Premier Asset Mgmt Llc owns 33,507 shares. Suntrust Banks Inc reported 1,156 shares. Hellman Jordan Mngmt Ma invested 4.18% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Moreover, Central National Bank And Com has 0.98% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Harding Loevner Ltd Partnership holds 680,731 shares. Mariner Limited Liability Com reported 0% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Plante Moran Fincl Advisors Ltd Co, a Michigan-based fund reported 89 shares. Ubs Asset Americas Incorporated accumulated 324,356 shares.

More notable recent Heron Therapeutics, Inc. (NASDAQ:HRTX) news were published by: Seekingalpha.com which released: “Heron’s Way Ahead: Is There Further Upside? – Seeking Alpha” on August 28, 2018, also Seekingalpha.com with their article: “Heron Therapeutics: Updates To Thesis And PDUFA Date Coming Up – Seeking Alpha” published on January 16, 2019, Seekingalpha.com published: “Heron Therapeutics down 4% premarket ahead of block trade – Seeking Alpha” on September 12, 2018. More interesting news about Heron Therapeutics, Inc. (NASDAQ:HRTX) were released by: Seekingalpha.com and their article: “FDA OKs expanded label for Heron’s Cinvanti – Seeking Alpha” published on February 26, 2019 as well as Streetinsider.com‘s news article titled: “Pacira Pharmaceuticals (PCRX) KOL Call Highlights Both Exparel and HTX-011 – StreetInsider.com” with publication date: April 09, 2019.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.